Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 3
1957 9
1958 10
1959 7
1960 12
1961 6
1962 4
1963 1
1966 5
1967 3
1968 3
1969 2
1971 2
1972 1
1973 7
1974 6
1975 1
1976 8
1977 5
1978 4
1979 9
1980 6
1981 4
1982 5
1983 11
1984 13
1985 7
1986 12
1987 8
1988 3
1989 9
1990 5
1991 9
1992 5
1993 6
1994 4
1995 1
1996 4
1997 5
1998 2
1999 10
2000 5
2001 10
2002 10
2003 10
2004 4
2005 13
2006 12
2007 23
2008 21
2009 34
2010 26
2011 25
2012 29
2013 37
2014 35
2015 48
2016 56
2017 46
2018 49
2019 39
2020 68
2021 59
2022 68
2023 65
2024 95
2025 39

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,052 results

Results by year

Filters applied: . Clear all
Page 1
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.
Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, Ostberg JR, Aguilar B, Wagner JR, Paul JA, Starr R, Wong RA, Chen W, Shulkin N, Aftabizadeh M, Filippov A, Chaudhry A, Ressler JA, Kilpatrick J, Myers-McNamara P, Chen M, Wang LD, Rockne RC, Georges J, Portnow J, Barish ME, D'Apuzzo M, Banovich NE, Forman SJ, Badie B. Brown CE, et al. Among authors: chaudhry a. Nat Med. 2024 Apr;30(4):1001-1012. doi: 10.1038/s41591-024-02875-1. Epub 2024 Mar 7. Nat Med. 2024. PMID: 38454126 Free PMC article. Clinical Trial.
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M, Flinn IW, Levy MY, Porter RF, Burke JM, Zafar SF, Misleh J, Kingsley EC, Yimer HA, Freeman B, Rao SS, Chaudhry A, Tumula PK, Gandhi MD, Manda S, Chen DY, By K, Xu L, Liu Y, Crescenzo R, Idoine A, Zhang X, Cohen A, Huang J, Sharman JP. Shadman M, et al. Among authors: chaudhry a. Lancet Haematol. 2023 Jan;10(1):e35-e45. doi: 10.1016/S2352-3026(22)00320-9. Epub 2022 Nov 16. Lancet Haematol. 2023. PMID: 36400069 Clinical Trial.
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.
Dorff TB, Blanchard MS, Adkins LN, Luebbert L, Leggett N, Shishido SN, Macias A, Del Real MM, Dhapola G, Egelston C, Murad JP, Rosa R, Paul J, Chaudhry A, Martirosyan H, Gerdts E, Wagner JR, Stiller T, Tilakawardane D, Pal S, Martinez C, Reiter RE, Budde LE, D'Apuzzo M, Kuhn P, Pachter L, Forman SJ, Priceman SJ. Dorff TB, et al. Among authors: chaudhry a. Nat Med. 2024 Jun;30(6):1636-1644. doi: 10.1038/s41591-024-02979-8. Epub 2024 Jun 12. Nat Med. 2024. PMID: 38867077 Free PMC article. Clinical Trial.
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.
Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, Jiménez-Ubieto A, Tessoulin B, Poon LM, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano L, Iskierka-Jażdżewska E, Tani M, Shen B, Uppala A, Zhu M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Luminari S; ELM-2 Investigators. Kim TM, et al. Among authors: chaudhry a. Ann Oncol. 2024 Nov;35(11):1039-1047. doi: 10.1016/j.annonc.2024.08.2239. Epub 2024 Aug 13. Ann Oncol. 2024. PMID: 39147364 Free article. Clinical Trial.
Infantile Bednar's aphthae.
Chaudhry A. Chaudhry A. J Paediatr Child Health. 2021 Oct;57(10):1717. doi: 10.1111/jpc.1_15383. J Paediatr Child Health. 2021. PMID: 34596281 No abstract available.
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Brouwer-Visser J, Fiaschi N, Deering RP, Cygan KJ, Scott D, Jeong S, Boucher L, Gupta NT, Gupta S, Adler C, Topp MS, Bannerji R, Duell J, Advani RH, Flink DM, Chaudhry A, Thurston G, Ambati SR, Jankovic V. Brouwer-Visser J, et al. Among authors: chaudhry a. J Immunother Cancer. 2024 Mar 21;12(3):e008338. doi: 10.1136/jitc-2023-008338. J Immunother Cancer. 2024. PMID: 38519055 Free PMC article.
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).
Vaishampayan UN, Muzaffar J, Winer I, Rosen SD, Hoimes CJ, Chauhan A, Spreafico A, Lewis KD, Bruno DS, Dumas O, McDermott DF, Strauss JF, Chu QS, Gilbert L, Chaudhry A, Calvo E, Dalal R, Boni V, Ernstoff MS, Velcheti V. Vaishampayan UN, et al. Among authors: chaudhry a. J Immunother Cancer. 2024 Nov 20;12(11):e010143. doi: 10.1136/jitc-2024-010143. J Immunother Cancer. 2024. PMID: 39567211 Free PMC article. Clinical Trial.
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
Lu S, Ahn MJ, Reungwetwattana T, Özgüroğlu M, Kato T, Yang JC, Huang M, Fujiki F, Inoue T, Quang LV, Sriuranpong V, Vicente D, Fuentes C, Chaudhry AA, Poole L, Armenteros Monterroso E, Rukazenkov Y, van der Gronde T, Ramalingam SS. Lu S, et al. Among authors: chaudhry aa. Ann Oncol. 2024 Dec;35(12):1116-1125. doi: 10.1016/j.annonc.2024.08.2243. Epub 2024 Sep 16. Ann Oncol. 2024. PMID: 39289145 Free article. Clinical Trial.
Role of theranostics in thoracic oncology.
Filippov A, Bonjoc KC, Chea J, Bowles N, Poku E, Chaudhry A. Filippov A, et al. Among authors: chaudhry a. J Thorac Dis. 2020 Sep;12(9):5140-5146. doi: 10.21037/jtd-2019-pitd-13. J Thorac Dis. 2020. PMID: 33145091 Free PMC article. Review.
Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy.
Farzeen Z, Khan RRM, Chaudhry AR, Pervaiz M, Saeed Z, Rasheed S, Shehzad B, Adnan A, Summer M. Farzeen Z, et al. Among authors: chaudhry ar. J Oncol Pharm Pract. 2024 Dec;30(8):1411-1431. doi: 10.1177/10781552241265058. Epub 2024 Jul 26. J Oncol Pharm Pract. 2024. PMID: 39056234 Review.
1,052 results